Details of the Drug

General Information of Drug (ID: DMXLYQF)

Drug Name

Belatacept

Synonyms

Nulojix (TN); Belatacept (USAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Kidney transplant rejection	NE84	Approved	[1]
Heart transplant rejection	NE84	NDA filed	[1]
------------------------------------------------------------------------------------

Sequence

MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTF
LDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPC
PDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 9.8 days [2]
Metabolism: The drug is metabolized via proteolytic enzymes []
Vd: The volume of distribution (Vd) of drug is 0.11 L/kg []

Cross-matching ID

DrugBank ID: DB06681
TTD ID: D0N4HB

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Belatacept (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Belatacept and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[4]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Belatacept and Tecfidera.	Multiple sclerosis [8A40]	[5]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Belatacept and Siponimod.	Multiple sclerosis [8A40]	[6]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Belatacept and Fingolimod.	Multiple sclerosis [8A40]	[7]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Belatacept and Ocrelizumab.	Multiple sclerosis [8A40]	[8]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Belatacept and Ozanimod.	Multiple sclerosis [8A40]	[9]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Belatacept when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[10]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6892).
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
4	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
5	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
6	Cerner Multum, Inc. "Australian Product Information.".
7	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
8	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]